Sign in8 stories
The August 26, 2026 8-K reconciles PRC GAAP and US GAAP accounting differences and breaks out research and development spending for key pipeline products for the first half of 2026.
SEC filing
The approval triggers a $250 million milestone payment to Zymeworks from partner Jazz Pharmaceuticals, with more payments and royalties possible.
SEC filing
Jazz Pharmaceuticals said the agency cleared zanidatamab-hrii with and without tislelizumab plus chemotherapy for all HER2+ patients regardless of PD-L1 status.
SEC filing
Positive MANGROVE data in mantle cell lymphoma, an FDA accelerated approval for BEQALZI, and a raised 2026 revenue outlook of $6.6–$6.8 billion highlight the update.
SEC filing